• Peter G. Pappas


Terbinafine is an oral and topical antifungal agent in the allylamine class of antifungal compounds [1]. Discovered in 1983, it is closely related to naftifine. It became available in Europe in 1991, and in 1996 in the United States. Terbinafine is the only oral allylamine available in the United States and is used largely for the treatment of superficial fungal infections, especially those due to dermatophytes. There has been significant interest in developing the drug for the treatment of deep mycoses, either alone or in combination, for disorders such as cryptococcosis, invasive aspergillosis, and other mould infections, but there are only scant clinical data evaluating its efficacy in these settings. Terbinafine is a valuable antifungal drug for the treatment of superficial fungal infections, and has potential as an adjunctive agent in the treatment of selected deep mycoses.


Invasive Aspergillosis Bullous Pemphigoid Clinical Cure Rate Tinea Capitis Tinea Pedis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science. 1984;224:1239–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992;43:259–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Ryder NS, Dupont MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of fungal and mammalian enzymes. Biochem J. 1985;230:765–70.PubMedGoogle Scholar
  4. 4.
    Birnbaum JE. Pharmacology of allylamines. J Am Acad Dermatol. 1990;23:782–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126 Suppl 39:2–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Schuster I. The interaction of representative members from two classes of antimycotics – the azoles and the allylamines – with cytochromes P450 in steroidogenic tissues and liver. Xenobiotica. 1985;15:29–46.CrossRefGoogle Scholar
  7. 7.
    Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol. 1999;141 Suppl 56:26–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother. 1987;31:1365–8.PubMedGoogle Scholar
  9. 9.
    Rinaldi MG. In vitro susceptibility of dermatophytes to antifungal drugs. Int J Dermatol. 1993;32:502–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother. 1997;8:275–87.Google Scholar
  11. 11.
    Arzeni D, Barchiesi F, Compagnuci P, et al. In vitro activity of terbinafine against clinical isolates of dermatophytes. Med Mycol. 1998;36:235–7.PubMedGoogle Scholar
  12. 12.
    Gupta AK, Kohli Y. Clinical and laboratory investigations. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluatin of combination antifungal activity. Br J Dermatol. 2003;149:296–305.CrossRefPubMedGoogle Scholar
  13. 13.
    Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 1987;32:1619–23.Google Scholar
  14. 14.
    Ryder NS, Leitner L. Activity of terbinafine against Aspergillus in vitro, in combination with amphotericin B or triazoles. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans: American Society for Microbiology, 1996 Abstract E54.Google Scholar
  15. 15.
    Schiraldi GF, Colombo MD. Potential use of terbinafine in the treatment of aspergillosis. Rev Contemp Pharmacother. 1997;8:349–56.Google Scholar
  16. 16.
    Shadomy S, Espinel-Ingroff A, Gebhart RJ. In vitro studies with SF 86–327, a new orally active allylamine derivative. Sabouraudia. 1985;23:125–32.PubMedGoogle Scholar
  17. 17.
    Venugopal PV, Venugopal TV, Ramakrishna ES, Illavarasin S. Antifungal activity of allylamines against agents of eumycetoma. Indian J Dermatol Venereol Leprol. 1993;59:239–42.Google Scholar
  18. 18.
    Wong PK, Ching WT, Gwon-Chung KJ, Meyer RD. Disseminated Phialophora parasitica infection in humans: case report and review. Rev Infect Dis. 1989;11:770–5.PubMedGoogle Scholar
  19. 19.
    Rallis E. Successful treatment of subcutaneous phaeohyphomycosis owing to Exophiala jeanselmei with oral terbinafine. Int J Dermatol. 2006;45:1369–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Bryan CS, Smith CW, Berg DE, Karp RB. Curvularia lunata endocarditis treated with terbinafine: case report. Clin Infect Dis. 1993;16:30–2.PubMedGoogle Scholar
  21. 21.
    Chang B, Sun PL, Huang FY, et al. Paecilomyces lilacinus peritonitis complicating peritoneal dialysis cured by oral voriconazole and terbinafine combination therapy. J Med Microbiol. 2008;57:1581–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Sellier P, Monsuez JJ, Lacroix C, et al. Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient. Clin Infect Dis. 2000;30:820–3.CrossRefPubMedGoogle Scholar
  23. 23.
    Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis. 2007;39:87–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Tong SYC, Peleg AY, Yoong J, Handke R, Szer J, Slavin M. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis. 2007;9:241–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Kesson AM, Bellemore MC, O’Mara TJ, Ellis DH, Sorrell TC. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis. 2009;48:1257–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Hiratani T, Asagi Y, Yamaguchi H. Evaluation of in vitro antimycotic activity of terbinafine, a new allylamine agent. Jpn J Med Mycol. 1991;32:323–32.CrossRefGoogle Scholar
  27. 27.
    Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother. 1998;42:1057–61.PubMedGoogle Scholar
  28. 28.
    Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol. 2000;38:155–9.PubMedGoogle Scholar
  29. 29.
    Cavalheiro AS, Maboni G, de Azevedo MI, et al. In vitro activity of terbinafine combined with caspofungin and azoles against Pythium insidiosum. Antimicrob Agents Chemother. 2009;53:2136–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Cavalheiro AS, Zanette RA, Spader TB, et al. In vitro activity of terbinafine associated to amphotericin B, fluvastatin, rifampicin, metronidazole and ibuprofen against Pythium insidiosum. Vet Microbiol. 2009;137:408–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Brown TA, Grooters AM, Hosgood GL. In vitro susceptibility of Pythium insidiosum and a Lagenidium sp to itraconazole, posaconazole, voriconazole, terbinafine, caspofungin, and mefenoxam. Am J Vet Res. 2008;69:1463–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Jensen JC. Clinical pharmacokinetics of terbinafine. Clin Exp Dermatol. 1989;14:110–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Faergemann J. Pharmacokinetics of terbinafine. Rev Contemp Pharmacother. 1997;8:289–97.Google Scholar
  34. 34.
    Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol. 1995;132:98–105.CrossRefPubMedGoogle Scholar
  35. 35.
    Faergemann J, Zehender H, Denouel J, Hilarious L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair, and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Dermatol Venereol. 1993;73:305–9.Google Scholar
  36. 36.
    Faergemann J, Zehender H, Denouel J, Hilarious L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis without stratum corneum), sebum, hair, and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol. 1994;19:121–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Humbert H, Cabiac MD, Denouel J, Kirkesseli S. Pharmacokinetics of terbinafine and its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos. 1995;16:685–94.CrossRefPubMedGoogle Scholar
  38. 38.
    Zehender H, Cabiac MD, Denouel J, Faergemann J, Donatsch P, Kutz K. Elimination kinetics of terbinafine from human plasma and tissue following multiple-dose administration, and comparison with 3 main metabolites. Drug Invest. 1994;8:203–10.Google Scholar
  39. 39.
    Hill S, Thomas R, Smith SG. An investigation of the pharmacokinetics of topical terbinafine 1% cream. Br J Dermatol. 1992;127:396–400.CrossRefPubMedGoogle Scholar
  40. 40.
    Faergemann J, Zehender H, Boukhabza A, Ganslandt J, Jones TC. Comparison of terbinafine levels in stratum corneum and dermis-epidermis (without stratum corneum) after topical or topical combined with oral therapy in healthy volunteers. J Eur Acad Dermatol Venereol. 1995;5 Suppl 1:S94.CrossRefGoogle Scholar
  41. 41.
    Roberts DT. The clinical efficacy of terbinafine in the treatment of fungal infections of nails. Rev Contemp Pharmacother. 1997;8:299–312.Google Scholar
  42. 42.
    Hull PR, Vismer HF. Potential use of terbinafine in the treatment of cutaneous sporotrichosis. Rev Contemp Pharmacother. 1997;8:343–7.Google Scholar
  43. 43.
    Chapman SW, Pappas P, Kauffman C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day−1) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47:62–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995;8:240–59.PubMedGoogle Scholar
  45. 45.
    Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol. 1995;34:138–43.CrossRefPubMedGoogle Scholar
  46. 46.
    Hofmann H, Brautigam M, Weidinger G, Zaun H, Lagos II. Treatment of toenail onychomycosis. Arch Dermatol. 1995;131:919–22.CrossRefPubMedGoogle Scholar
  47. 47.
    Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother. 1997;31:445–56.PubMedGoogle Scholar
  48. 48.
    Zaias N, Serrano L. The successful treatament of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol. 1989;14:120–3.CrossRefPubMedGoogle Scholar
  49. 49.
    Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol. 1992;126 Suppl 39:40–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Goodfield MJ, Andrew L, Evans EG. Short-term treatment of dermatophyte onychomycosis with terbinafine. Br Med J. 1992;304:1151–4.CrossRefGoogle Scholar
  51. 51.
    Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathology. 2008;166:353–67.CrossRefGoogle Scholar
  52. 52.
    Gupta AK, Lynch LE, Kogan N, Cooper EA. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol. 2009;23:256–62.CrossRefPubMedGoogle Scholar
  53. 53.
    Criber BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br J Dermatol. 2004;150:414–20.CrossRefGoogle Scholar
  54. 54.
    Albanese G, DiCintio R, Martini C, Nocoletti A. Short therapy for tinea unguium with terbinafine: four different courses of treatment. Mycoses. 1995;38:211–4.CrossRefPubMedGoogle Scholar
  55. 55.
    Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol. 1995;32:750–3.CrossRefPubMedGoogle Scholar
  56. 56.
    Haneke E, Tausch I, Brautigam M, Weidinger G, Welzel D. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol. 1995;32:72–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Brautigam M, Nolting S, Schopf RE, Weidinger G. Randomized double-blind comparison of terbinafine and itraconazole for the treatment of toenail tinea infections. Br Med J. 1995;311:919–22.Google Scholar
  58. 58.
    Ghannoum MA, Wraith LA, Cai B, Nyirady J, Isham N. Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial. Br J Dermatol. 2008;159:711–3.CrossRefPubMedGoogle Scholar
  59. 59.
    Haroon TS, Hussain I, Mahmood A, Nagi AH, Ahman D, Zahid M. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol. 1992;126 Suppl 39:47–50.CrossRefPubMedGoogle Scholar
  60. 60.
    Gupta AK, Adamiak A, Cooper EA. The efficacy and safety of terbinafine in children. J Eur Acad Dermatol Venereol. 2003;17:627–40.CrossRefPubMedGoogle Scholar
  61. 61.
    Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol. 1992;126:51–5.CrossRefPubMedGoogle Scholar
  62. 62.
    Kudoh K, Kamei E, Terunama A, Nakagawa S, Tagami H. Successful treatment of cutaneous sporotrichosis with terbinafine. J Dermatol Treat. 1996;7:33–5.CrossRefGoogle Scholar
  63. 63.
    Coskun B, Saral Y, Akpolat N, Ataseven A, Çiçek D. Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature. Mycopathology. 2004;158:53–6.CrossRefGoogle Scholar
  64. 64.
    Restrepo A, Robledo J, Gomez I, Tabares AM, Gutierrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol. 1986;122:413–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Esterre P, Ratsioharana M, Roig P. Potential use of terbinafine in the treatment of chromoblastomycosis. Rev Contemp Pharmacother. 1997;8:357–62.Google Scholar
  66. 66.
    Esterre P, Intani C, Ratsioharana M, Andriantsmahavandy A. A multicenter trial of terbinafine in patients with chromoblastomycosis: effect on clinical and biologic criteria. J Dermatol Treat. 1998;9:529–34.CrossRefGoogle Scholar
  67. 67.
    Zhang J, Xi L, Lu C, et al. Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: a report of three cases in Guangdong, China. Mycoses. 2008;52:176–81.CrossRefPubMedGoogle Scholar
  68. 68.
    Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47:3–15.CrossRefPubMedGoogle Scholar
  69. 69.
    Zhang JM, Xi LY, Zhang H, et al. Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora. Eur J Dermatol. 2009;19:451–5.PubMedGoogle Scholar
  70. 70.
    Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol. 1999;141 Suppl 56:36–40.CrossRefPubMedGoogle Scholar
  71. 71.
    Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis. 2003;37:S188–224.CrossRefPubMedGoogle Scholar
  72. 72.
    Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, Revankar SG. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. Diagn Microbiol Infect Dis. 2008;62:443–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Harari S, Schiraldi GF, de Juli E, Gronda E. Relapsing Aspergillus bronchitis in a double lung transplant patient, successfully treated with a new oral antimycotic agent [Letter]. Chest. 1997;111:835–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Hall M, Monka C, Krupp P, O’Sullivan D. Safety of oral terbinafine: results of a post marketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133:1213–9.CrossRefPubMedGoogle Scholar
  75. 75.
    Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120:791–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Gupta AK, Sibbald RG, Knowles SR, Lynde CW, Shear NH. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol. 1997;36:858–62.CrossRefPubMedGoogle Scholar
  77. 77.
    Bennett ML, Jorizzo JL, White WL. Generalized pustular eruptions associated with oral terbinafine. Int J Dermatol. 1999;38:596–600.CrossRefPubMedGoogle Scholar
  78. 78.
    Beltraminelli HS, Lerch M, Arnold A, Bircher AJ, Haeusermann P. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol. 2005;152:780–3.CrossRefPubMedGoogle Scholar
  79. 79.
    Gupta AK, Del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol. 1998;23:64–7.CrossRefPubMedGoogle Scholar
  80. 80.
    Conjeevaram G, Vongthavaravat V, Summer R, Koff RS. Terbinafine-induced hepatitis and pancytopenia. Dig Dis Sci. 2001;46:1714–6.CrossRefPubMedGoogle Scholar
  81. 81.
    Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol. 2003;2:47–51.PubMedGoogle Scholar
  82. 82.
    Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am J Med Sci. 2003;325:292–5.CrossRefPubMedGoogle Scholar
  83. 83.
    Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol. 1998;93:459–60.CrossRefPubMedGoogle Scholar
  84. 84.
    Perveze Z, Johnson MW, Rubin RA, et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 2007;13:162–4.CrossRefPubMedGoogle Scholar
  85. 85.
    Gupta AK, Soori GS, Del Rossa JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol. 1998;38:765–7.CrossRefPubMedGoogle Scholar
  86. 86.
    Shapiro M, Li L, Miller J. Terbinafine-induced neutropenia. Br J Dermatol. 1999;140:1169–99.Google Scholar
  87. 87.
    Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol. 1994;31:806.CrossRefPubMedGoogle Scholar
  88. 88.
    Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents – terbinafine, fluconazole, and itraconazole. Int J Dermatol. 1998;37:410–5.CrossRefPubMedGoogle Scholar
  89. 89.
    Carstens J, Wendelboe P, Sogaard H, Thestrup-Pederson K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Dermatol Venereol. 1994;74:391–2.Google Scholar
  90. 90.
    Aksakal BA, Ozsoy E, Arnavut O, Ali Gürer M. Oral terbinafine-induced bullous pemphigoid. Ann Pharmacother. 2003;37:1625–7.CrossRefPubMedGoogle Scholar
  91. 91.
    McKay DA, Schofield OM, Benton EC. Terbinafine-induced subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2004;84:472–4.CrossRefPubMedGoogle Scholar
  92. 92.
    Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematous. Dermatology. 2006;212:59–65.CrossRefPubMedGoogle Scholar
  93. 93.
    Lorentz K, Booken N, Goerdt S, Goebeler M. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. J Dtsch Dermatol Ges. 2008;6:823–7.PubMedGoogle Scholar
  94. 94.
    Hivnor CM, Hudkins ML, Bonner B. Terbinafine-induced subacute cutaneous lupus erythematosus. Cutis. 2008;81:156–7.PubMedGoogle Scholar
  95. 95.
    Magro CM, Schaefer JT, Waldeman J, Knight D, Seilstad K, Hearne D. Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis. J Cutan Pathol. 2008;35:74–91.CrossRefPubMedGoogle Scholar
  96. 96.
    Yülek F, Cagil N, Cakmak HB, Akcay EK, Imek A, Kansu T. Bilateral anterior optic neuropathy associated with use of terbinafine. Clin Exp Ophthalmol. 2008;36:488–9.CrossRefGoogle Scholar
  97. 97.
    Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Man. 2005;1:299–306.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Infectious DiseasesUniversity of Alabama at Birmingham, School of MedicineBirminghamUSA

Personalised recommendations